약학회지
YAKHAK HOEJI
ISSN 0377-9556 (PRINT)
ISSN 2383-9457 (ONLINE)

Table. 5.

Table. 5.

The status of development of biosimilar recombinant products in Korea (2020)

Company name Brand name Treatment area Original medicines Target market
Dong-A ST DA-3880 Anemia (long-lasting) Darbepoetin alpha Japan

Chong Kun Dang CKD-11191 Anemia Nesp Japan
CKD-701 Macular degeneration Lucentis

inno. N (CJ Healthcare) CJ-4001 Anemia (long-lasting) Darbepoetin alpha Japan, China

DM Bio DMB-311 Breast cancer Herceptin Japan
DMB-3115 Psoriasis Stelara

Alteogen ALT-L9 Macular degeneration EyLea Japan, China, Brazil
ALT-P7 Breast cancer Herceptin

AProgen N1-071 Rheumatoid arthritis Remicade Japan
AP-063 Breast cancer Herceptin
AP-056 Non-Hodgkin lymphona Rituxan

Prestige Biologics HD 201 Breast cancer Herceptin Europe
HD 204 Colon cancer Avastin
PBP 1502 Rheumatoid arthritis Humira

ISU abxis ISU 106 Lung cancer Opdivo N/A

Samsung Bioepis SB 8 Lung cancer Avastin Global market
SB11 Macular degeneration Lucentis
SB12 Hemoglobinuria Solilis
SB15 Macular degeneration EyLea

Celltrion CT-P39 Asthma Xolar Europe, USA
CT-P17 Rheumatoid arthritis Humira
CT-P16 Lung cancer Avastin

Yakhak Hoeji 2021;65:1-9 https://doi.org/10.17480/psk.2021.65.1.1
© 2021 Yakhak Hoeji